drugset / Trial / NCT01448720

Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate

NCT01448720

Phase 3 Completed 142 enrolled Janssen-Cilag Farmaceutica Ltda.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to explore the efficacy of paliperidone palmitate administered as a once monthly injection in patients with an acute exacerbation of schizophrenia.

Timeline

Start
2011-09
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject paliperidone palmitate Unknown 75 mg Intramuscular

Indications